Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.
Jordan University of Science and Technology, Irbid, Jordan.
J Gen Intern Med. 2023 Aug;38(10):2289-2297. doi: 10.1007/s11606-023-08059-w. Epub 2023 Feb 14.
Medical hospitalizations for people with opioid use disorder (OUD) frequently result in patient-directed discharges (PDD), often due to untreated pain and withdrawal.
To investigate the association between early opioid withdrawal management strategies and PDD.
Retrospective cohort study using three datasets representing 362 US hospitals.
Adult patients hospitalized between 2009 and 2015 with OUD (as identified using ICD-9-CM codes or inpatient buprenorphine administration) and no PDD on the day of admission.
Opioid withdrawal management strategies were classified based on day-of-admission receipt of any of the following treatments: (1) medications for OUD (MOUD) including methadone or buprenorphine, (2) other opioid analgesics, (3) adjunctive symptomatic medications without opioids (e.g., clonidine), and (4) no withdrawal treatment.
PDD was assessed as the main outcome and hospital length of stay as a secondary outcome.
Of 6,715,286 hospitalizations, 127,158 (1.9%) patients had OUD and no PDD on the day of admission, of whom 7166 (5.6%) had a later PDD and 91,051 (71.6%) patients received some early opioid withdrawal treatment (22.3% MOUD; 43.4% opioid analgesics; 5.9% adjunctive medications). Compared to no withdrawal treatment, MOUD was associated with a lower risk of PDD (adjusted odds ratio [aOR] = 0.73, 95%CI 0.68-0.8, p < .001), adjunctive treatment alone was associated with higher risk (aOR = 1.13, 95%CI: 1.01-1.26, p = .031), and treatment with opioid analgesics alone was associated with similar risk (aOR 0.95, 95%CI: 0.89-1.02, p = .148). Among those with PDD, both MOUD (adjusted incidence rate ratio [aIRR] = 1.24, 95%CI: 1.17-1.3, p < .001) and opioid analgesic treatments (aIRR = 1.39, 95%CI: 1.34-1.45, p < .001) were associated with longer hospital stays.
MOUD was associated with decreased risk of PDD but was utilized in < 1 in 4 patients. Efforts are needed to ensure all patients with OUD have access to effective opioid withdrawal management to improve the likelihood they receive recommended hospital care.
患有阿片类药物使用障碍(OUD)的人经常因未经治疗的疼痛和戒断而导致患者定向出院(PDD)。
研究早期阿片类药物戒断管理策略与 PDD 之间的关系。
使用代表 362 家美国医院的三个数据集的回顾性队列研究。
2009 年至 2015 年间住院且患有 OUD 的成年患者(通过 ICD-9-CM 代码或住院丁丙诺啡给药确定),入院当天无 PDD。
根据入院当天接受以下任何治疗的患者,对阿片类药物戒断管理策略进行分类:(1)阿片类药物使用障碍药物(MOUD),包括美沙酮或丁丙诺啡,(2)其他阿片类镇痛药,(3)无阿片类药物的辅助对症药物(例如,可乐定),以及(4)无戒断治疗。
PDD 为主要结局,住院时间为次要结局。
在 6715286 例住院患者中,有 127158 例(1.9%)患者入院当天患有 OUD 且无 PDD,其中 7166 例(5.6%)后来发生 PDD,91051 例(71.6%)患者接受了某种早期阿片类药物戒断治疗(22.3% MOUD;43.4%阿片类镇痛药;5.9%辅助药物)。与无戒断治疗相比,MOUD 与较低的 PDD 风险相关(调整后的优势比[aOR] = 0.73,95%CI 0.68-0.8,p < 0.001),单独使用辅助治疗的风险更高(aOR = 1.13,95%CI:1.01-1.26,p = 0.031),单独使用阿片类镇痛药的风险相似(aOR 0.95,95%CI:0.89-1.02,p = 0.148)。在发生 PDD 的患者中,MOUD(调整后的发病率比[aIRR] = 1.24,95%CI:1.17-1.3,p < 0.001)和阿片类镇痛药治疗(aIRR = 1.39,95%CI:1.34-1.45,p < 0.001)都与住院时间延长有关。
MOUD 与 PDD 风险降低有关,但只有不到 1/4 的患者接受了 MOUD。需要努力确保所有患有 OUD 的患者都能获得有效的阿片类药物戒断管理,以提高他们接受推荐的医院护理的可能性。